SG3 Management’s Clovis Oncology, Inc. CLVS Stock Holding History

SG3 Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-40,000	Closed	-$270K	–	1120
2020 Q2	$270K	Hold	40,000	–	–	0.02%	452
2020 Q1	$254K	Buy	+40,000	New	+$321K	0.03%	229

Other funds holding CLVS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

SG3 Management's CLVS Position: Q3 2020 in Review

SG3 Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2020, closing a stake of 5,500 shares — an estimated $37K sold.

SG3 Management first reported a position in CLVS in Q1 2020 and held it in 2 quarters. The position peaked at $64K in Q1 2020. 169 funds tracked by Wall St. Rank hold CLVS as of Q3 2020.

SG3 Management reported no remaining Clovis Oncology, Inc. position as of Q3 2020 after selling out during the quarter.
SG3 Management sold 5,500 Clovis Oncology, Inc. shares in Q3 2020, an estimated $37K.
SG3 Management first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 2 quarters.
SG3 Management's Clovis Oncology, Inc. position peaked at $64K in Q1 2020.
169 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2020.

Based on SG3 Management's 13F filing for Q3 2020, filed 13 Nov 2020.